MX2015008313A - Terapia de combinacion de anticuerpos anti-her3. - Google Patents

Terapia de combinacion de anticuerpos anti-her3.

Info

Publication number
MX2015008313A
MX2015008313A MX2015008313A MX2015008313A MX2015008313A MX 2015008313 A MX2015008313 A MX 2015008313A MX 2015008313 A MX2015008313 A MX 2015008313A MX 2015008313 A MX2015008313 A MX 2015008313A MX 2015008313 A MX2015008313 A MX 2015008313A
Authority
MX
Mexico
Prior art keywords
her3
combination therapy
her2 antibodies
antibodies
her2
Prior art date
Application number
MX2015008313A
Other languages
English (en)
Inventor
Birgit Bossenmaier
Christian Gerdes
Marlene Thomas
Frieder Bauss
Thomas Friess
Max Hasmann
Martin Weisser
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2015008313A publication Critical patent/MX2015008313A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a la terapia de combinación de anticuerpos anti-HER3 con determinados anticuerpos anti-HER.
MX2015008313A 2013-01-11 2014-01-10 Terapia de combinacion de anticuerpos anti-her3. MX2015008313A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13151076 2013-01-11
PCT/EP2014/050344 WO2014108484A2 (en) 2013-01-11 2014-01-10 Combination therapy of anti-her3 antibodies

Publications (1)

Publication Number Publication Date
MX2015008313A true MX2015008313A (es) 2015-11-11

Family

ID=47504772

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015008313A MX2015008313A (es) 2013-01-11 2014-01-10 Terapia de combinacion de anticuerpos anti-her3.

Country Status (19)

Country Link
US (2) US9180185B2 (es)
EP (1) EP2943508B1 (es)
JP (1) JP6257646B2 (es)
KR (1) KR20150093231A (es)
CN (1) CN104797602A (es)
AR (1) AR094403A1 (es)
AU (1) AU2014204795A1 (es)
CA (1) CA2887508A1 (es)
CL (1) CL2015001049A1 (es)
CR (1) CR20150284A (es)
EA (1) EA201500744A1 (es)
HK (1) HK1211950A1 (es)
IL (1) IL238393A0 (es)
MA (1) MA38273A1 (es)
MX (1) MX2015008313A (es)
PH (1) PH12015501071A1 (es)
SG (1) SG11201503802UA (es)
TW (1) TW201431559A (es)
WO (1) WO2014108484A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
AR094403A1 (es) * 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
RU2019115089A (ru) 2013-04-16 2019-06-11 Дженентек, Инк. Варианты пертузумаба и их аналитическая характеристика
BR112016025056A2 (pt) 2014-05-14 2018-02-20 F. Hoffmann-La Roche Ag uso de pelo menos um polipeptídeo, anticorpo biespecífico, anticorpo biespecífico isolado, anticorpo her3/her2 biespecífico, célula hospedeira, método de produção do anticorpo biespecífico her3/her2, imunoconjugado e formulação farmacêutica
EP3091033A1 (en) * 2015-05-06 2016-11-09 Gamamabs Pharma Anti-human-her3 antibodies and uses thereof
CN108602890A (zh) 2015-12-11 2018-09-28 瑞泽恩制药公司 用于减少或预防对egfr和/或erbb3阻滞剂具有抗性的肿瘤生长的方法
WO2017102789A1 (en) * 2015-12-17 2017-06-22 F. Hoffmann-La Roche Ag Combination therapy of anti-her3 antibodies and anti-her2 antibodies
MA47313B1 (fr) 2017-01-17 2020-12-31 Hoffmann La Roche Formulations sous-cutanées d'anticorps her2
US20200061031A1 (en) 2017-02-28 2020-02-27 Kinki University Method for treating egfr-tki-resistant non-small cell lung cancer by administration of anti-her3 antibody-drug conjugate
HUE064898T2 (hu) 2017-03-02 2024-04-28 Genentech Inc HER2-pozitív emlõrák adjuváns kezelése
DK3645553T5 (da) 2017-06-27 2024-08-26 Regeneron Pharma Tropismemodificerede, rekombinante, virale partikler og anvendelser deraf til targeteret indføring af genetisk materiale i humane celler
CA3105750A1 (en) * 2018-07-09 2020-01-16 Precigen, Inc. Fusion constructs and methods of using thereof
CN112912109A (zh) 2018-09-20 2021-06-04 第一三共株式会社 通过施用抗her3抗体-药物缀合物治疗her3-突变的癌症
KR20240110556A (ko) * 2021-09-03 2024-07-15 캔써 리서치 테크놀로지 리미티드 Her3 항원-결합 분자를 사용한 암의 치료 및 예방

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
DE69233254T2 (de) 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanisierter Heregulin Antikörper
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
PT896586E (pt) 1996-03-27 2007-01-31 Genentech Inc Anticorpos de erbb3
CA2259222A1 (en) 1996-06-27 1997-12-31 Pfizer Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors
JPH11236333A (ja) 1997-12-30 1999-08-31 Pfizer Prod Inc 抗ガン剤として有用なイミダゾリン−４−オン誘導体
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
CN1314917A (zh) 1998-05-15 2001-09-26 伊姆克罗尼系统公司 用辐射和生长因子受体酪氨酸激酶抑制剂治疗人肿瘤
ATE289602T1 (de) 1998-08-27 2005-03-15 Pfizer Prod Inc Quinolin-2-on-derivate verwendbar als antikrebsmittel
CN1314904A (zh) 1998-08-27 2001-09-26 辉瑞产品公司 用作抗癌剂的炔基取代的喹啉－2－酮衍生物
EP1006113A1 (en) 1998-12-02 2000-06-07 Pfizer Products Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth
AP2001002241A0 (en) 1999-02-11 2001-09-30 Pfizer Prod Inc Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents.
US6586447B1 (en) 1999-04-01 2003-07-01 Pfizer Inc 3,3-disubstituted-oxindole derivatives useful as anticancer agents
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
AR024464A1 (es) 1999-06-25 2002-10-02 Genentech Inc Anticuerpos anti-erbb2 humanizados.
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
ATE259365T1 (de) 1999-11-30 2004-02-15 Pfizer Prod Inc Chinolinderivate verwendbar zur hemmung der farnesyl-protein transferase
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
EP1228766A1 (en) 2001-01-31 2002-08-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. PYK2 phosphorylation by HER3 induces tumor invasion
US7744882B2 (en) 2001-05-31 2010-06-29 Tumor Biology Investment Group, Inc. Soluble ErbB3 methods of detection and antibodies
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
DK1443961T3 (da) 2001-10-25 2009-08-24 Genentech Inc Glycoprotein-sammensætninger
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
EP2400021B1 (en) 2002-03-26 2016-11-30 Zensun (Shanghai) Science & Technology, Co., Ltd. ErbB3 based methods and compositions for treating neoplasms
CZ308720B6 (cs) 2003-01-22 2021-03-24 Roche Glycart Ag Fúzní konstrukty a jejich použití pro přípravu protilátek se zvýšenou vazebnou afinitou k receptorům Fc a efektorovou funkcí
WO2005011735A1 (en) 2003-07-29 2005-02-10 Morphotek, Inc. Antibodies and methods for generating genetically altered antibodies with enhanced effector function
EP1664116A4 (en) 2003-08-22 2009-06-03 Biogen Idec Inc IMPROVED ANTIBODIES WITH CHANGED EFFECTOR FUNCTION AND MANUFACTURING METHOD THEREFOR
WO2005027966A2 (en) 2003-09-05 2005-03-31 Genentech, Inc. Antibodies with altered effector functions
EP2348051B1 (en) 2003-11-05 2018-12-19 Roche Glycart AG CD20 antibodies with increased fc receptor binding affinity and effector function
EP2527460B1 (en) 2004-05-27 2014-12-24 The Regents of The University of Colorado Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients
SV2006002143A (es) 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
NZ553171A (en) 2004-09-08 2010-03-26 Genentech Inc Methods of using death receptor ligands and CD20 antibodies
US7632497B2 (en) 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
RU2007125644A (ru) 2004-12-07 2009-01-20 Дженентек Инк. (Us) Отбор пациентов для терапии ингибитором her
CA2596835C (en) 2005-02-07 2019-08-20 Glycart Biotechnology Ag Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
PL1850874T3 (pl) * 2005-02-23 2014-03-31 Genentech Inc Wydłużanie czasu do progresji choroby lub przeżycia u chorych na raka jajnika stosujących pertuzumab
US20060204505A1 (en) * 2005-03-08 2006-09-14 Sliwkowski Mark X Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs)
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
EP1877441A2 (en) 2005-04-26 2008-01-16 Bioren, Inc. Method of producing human igg antibodies with enhanced effector functions
CA2606102C (en) 2005-04-26 2014-09-30 Medimmune, Inc. Modulation of antibody effector function by hinge domain engineering
PE20070207A1 (es) 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
BRPI0615397B1 (pt) 2005-08-26 2023-10-03 Roche Glycart Ag Anticorpo anti-cd20, composição farmacêutica que o contém e uso do mesmo
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
JP5656406B2 (ja) 2006-11-28 2015-01-21 ユースリー ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツングＵ３ Ｐｈａｒｍａ ＧｍｂＨ 治療効力を予測するためのマーカーとしての活性化ｈｅｒ３
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
ES2631727T3 (es) 2007-02-16 2017-09-04 Merrimack Pharmaceuticals, Inc. Anticuerpos contra el ErbB3 y usos de los mismos
PL2162149T3 (pl) 2007-06-01 2014-04-30 Henry M Jackson Found Advancement Military Medicine Inc Szczepionka do zapobiegania nawrotowi raka sutka
EP2155786B1 (en) 2007-06-06 2015-11-18 F. Hoffmann-La Roche AG Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a nir fluorescence label
EP2138511A1 (en) 2008-06-27 2009-12-30 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. HER3 as a determinant for the prognosis of melanoma
AU2009281721A1 (en) 2008-08-15 2010-02-18 Merrimack Pharmaceuticals, Inc. Methods and systems for predicting response of cells to a therapeutic agent
WO2010052225A1 (en) 2008-11-04 2010-05-14 F. Hoffmann-La Roche Ag Modulators for her2 signaling in normal her2 expressing settings
US8349574B2 (en) 2009-01-15 2013-01-08 Laboratory Corporation Of America Holdings Methods of determining patient response by measurement of Her-3
RU2504553C2 (ru) * 2009-03-20 2014-01-20 Дженентек, Инк. Антитела к her
MX2011010166A (es) 2009-04-07 2011-10-11 Roche Glycart Ag Anticuerpos biespecificos anti-erbb-3/anti-c-met.
WO2010127181A1 (en) 2009-04-29 2010-11-04 Trellis Bioscience, Inc. Improved antibodies immunoreactive with heregulin-coupled her3
MX336091B (es) 2009-08-21 2016-01-08 Merrimack Pharmaceuticals Inc Anticuerpos contra el extodominio de erbb3 y usos de los mismos.
US20120195831A1 (en) 2009-10-09 2012-08-02 Ningyan Zhang Generation, characterization and uses thereof of anti-her3 antibodies
EP2496598B1 (en) 2009-11-04 2017-08-02 Affibody AB Her3 binding polypeptides
JP5931736B2 (ja) 2009-11-13 2016-06-08 ウー３・フアルマ・ゲー・エム・ベー・ハーＵ３ Ｐｈａｒｍａ Ｈｅｒ−３関連疾患を治療または予防するための物質および方法
SG181894A1 (en) * 2009-12-22 2012-08-30 Roche Glycart Ag Anti-her3 antibodies and uses thereof
DK2536748T3 (da) 2010-02-18 2014-10-13 Genentech Inc Neuregulin-antagonister og anvendelse deraf ved behandling af kræft
KR101798679B1 (ko) 2010-03-11 2017-11-16 메리맥 파마슈티컬즈, 인크. ３중 음성 및 기저형 유방암 치료 시의 ｅｒｂｂ３ 저해제의 용도
CA2795799C (en) 2010-04-09 2018-09-25 Aveo Pharmaceuticals, Inc. Anti-erbb3 antibodies
WO2012019024A2 (en) 2010-08-04 2012-02-09 Immunogen, Inc. Her3-binding molecules and immunoconjugates thereof
AU2011286407A1 (en) 2010-08-06 2013-02-21 Amgen Use of HER3 binding agents in prostate treatment
RS55930B1 (sr) 2010-08-20 2017-09-29 Novartis Ag Antitela za receptor 3 faktora rasta epiderma (her3)
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
AU2011307251A1 (en) 2010-09-30 2013-02-28 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-HER3 antibodies
WO2012052230A1 (en) 2010-10-18 2012-04-26 Mediapharma S.R.L. Erbb3 binding antibody
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
CA2816520C (en) 2010-11-01 2017-11-21 Symphogen A/S Anti-her3 antibodies and compositions
ITRM20100577A1 (it) 2010-11-02 2012-05-03 Takis Srl Immunoterapia contro il recettore erbb-3
SG192775A1 (en) 2011-03-15 2013-09-30 Merrimack Pharmaceuticals Inc Overcoming resistance to erbb pathway inhibitors
EP4234034A3 (en) 2011-10-14 2023-09-20 F. Hoffmann-La Roche AG Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab
DK2797957T3 (da) 2011-11-23 2019-09-23 Medimmune Llc Bindingsmolekyler specifikke for her3 og anvendelser deraf
CN104159924B (zh) * 2011-12-05 2018-03-16 诺华股份有限公司 表皮生长因子受体3(her3)的抗体
WO2013096812A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Articles of manufacture and methods for co-administration of antibodies
US8859797B1 (en) 2012-04-27 2014-10-14 Air Liquide Electronics U.S. Lp Synthesis methods for carbosilanes
JP6325527B2 (ja) 2012-05-02 2018-05-16 シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ ヒト化ｐａｎ−ｈｅｒ抗体組成物
AR094403A1 (es) * 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3

Also Published As

Publication number Publication date
EA201500744A1 (ru) 2015-12-30
KR20150093231A (ko) 2015-08-17
CN104797602A (zh) 2015-07-22
TW201431559A (zh) 2014-08-16
PH12015501071A1 (en) 2015-08-03
SG11201503802UA (en) 2015-08-28
WO2014108484A3 (en) 2014-09-04
CL2015001049A1 (es) 2015-10-16
AU2014204795A1 (en) 2015-04-30
CA2887508A1 (en) 2014-07-17
US20140227255A1 (en) 2014-08-14
MA38273A1 (fr) 2017-05-31
WO2014108484A2 (en) 2014-07-17
EP2943508A2 (en) 2015-11-18
US20160159912A1 (en) 2016-06-09
HK1211950A1 (en) 2016-06-03
IL238393A0 (en) 2015-06-30
JP6257646B2 (ja) 2018-01-10
EP2943508B1 (en) 2020-07-15
JP2016504399A (ja) 2016-02-12
AR094403A1 (es) 2015-07-29
CR20150284A (es) 2015-06-30
US9180185B2 (en) 2015-11-10

Similar Documents

Publication Publication Date Title
MX2015008313A (es) Terapia de combinacion de anticuerpos anti-her3.
MX2016003129A (es) Terapia de combinacion de anticuerpos contra el csf-1r humano y anticuerpos contralel pd-l1 humano.
PH12015502565A1 (en) Anti-transferrin receptor antibodies and methods of use
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
MX2021003704A (es) Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales.
TN2017000470A1 (en) Heterodimeric antibodies that bind cd3 and tumor antigens.
MX2015014500A (es) Terapia de combinacion de anticuerpos contra csf-1r y agonista de tlr9.
PH12016501143A1 (en) Anti-cd33 antibodies and immunoconjugates
MX2020002289A (es) Anticuerpos anti-alfa-sinucleina y metodos de uso.
PH12015501954A1 (en) Anti-b7-h4 antibodies and immunoconjugates
MX2015012326A (es) Anticuerpos anti-crth2 y su uso.
TN2017000246A1 (en) Anti-c10orf54 antibodies and uses thereof
PH12014502132A1 (en) Anti-lgr5 antibodies and immunoconjugates
MY176285A (en) Anti-fcrh5 antibodies
MX2016008099A (es) Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40.
IN2014DN05885A (es)
MX2016014862A (es) Her3 / her2 anticuerpos biespecificos que se unen a la horquilla beta de her3 y al dominio ii de her2.
MX2014014376A (es) Anticuerpos de anti-biotina y metodos de uso.
IN2013MU00848A (es)
MX353951B (es) Anticuerpos de anti-teofilina y metodos de uso.
PH12016501201A1 (en) Synthesis of ent-progesterone and intermediates thereof
MX2015012902A (es) Sintesis de ent-progesterona e intermediarios de la misma.
MX2015010789A (es) Anticuerpos anti-pcsm.